Nevertheless, research indicates that medications such as metformin, Glucagon-Like Peptide-1 agonists, and Dipeptidyl Peptidase IV inhibitors exhibit promise in diminishing the rate of advancement of conditions associated with metabolic syndrome [40,44]. This evidence concerns the gene DPP4 and metabolic syndrome.